| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 0450 |
Emergency room services |
43,425 |
39,963 |
$1.49M |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,193 |
5,044 |
$415K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
9,834 |
9,142 |
$386K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
8,901 |
8,481 |
$352K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,004 |
1,976 |
$327K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,995 |
2,940 |
$294K |
| J3490 |
Unclassified drugs |
22,661 |
11,781 |
$216K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
5,617 |
5,407 |
$201K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,855 |
2,692 |
$183K |
| 0270 |
|
16,832 |
9,137 |
$177K |
| 80053 |
Comprehensive metabolic panel |
19,832 |
18,646 |
$170K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,453 |
5,160 |
$160K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
1,227 |
1,176 |
$159K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,533 |
9,126 |
$157K |
| 0360 |
|
2,218 |
1,708 |
$155K |
| 99199 |
Unlisted special service, procedure or report |
5,944 |
5,481 |
$142K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,311 |
1,258 |
$129K |
| 71045 |
Radiologic examination, chest; single view |
13,769 |
13,260 |
$126K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,648 |
5,467 |
$113K |
| S3620 |
Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) |
756 |
643 |
$109K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
21,516 |
19,971 |
$102K |
| Z7502 |
|
2,809 |
2,771 |
$99K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,000 |
1,940 |
$83K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
1,463 |
1,426 |
$55K |
| 0250 |
|
7,788 |
4,512 |
$54K |
| 84484 |
|
7,942 |
7,453 |
$48K |
| 83690 |
|
7,744 |
7,385 |
$47K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,383 |
4,948 |
$46K |
| 85730 |
|
4,447 |
4,301 |
$39K |
| 83880 |
|
2,243 |
2,165 |
$38K |
| 0710 |
|
2,419 |
2,294 |
$37K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,337 |
1,295 |
$36K |
| 81001 |
|
13,245 |
12,718 |
$36K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
798 |
791 |
$35K |
| 81025 |
|
7,262 |
7,014 |
$33K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
319 |
309 |
$32K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,111 |
2,868 |
$30K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
5,131 |
4,995 |
$27K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
181 |
179 |
$26K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,265 |
4,951 |
$26K |
| 0301 |
|
241 |
215 |
$24K |
| 85610 |
|
6,273 |
6,044 |
$23K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,884 |
4,563 |
$23K |
| 87040 |
|
1,535 |
1,503 |
$21K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,499 |
1,416 |
$21K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
464 |
449 |
$20K |
| 76801 |
|
476 |
433 |
$19K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
2,951 |
2,487 |
$19K |
| A4217 |
Sterile water/saline, 500 ml |
2,087 |
1,947 |
$17K |
| 0272 |
|
3,060 |
2,920 |
$17K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
277 |
266 |
$16K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,640 |
2,513 |
$15K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,986 |
1,746 |
$14K |
| 73610 |
|
720 |
705 |
$14K |
| Z9725 |
|
318 |
317 |
$14K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,084 |
1,956 |
$13K |
| 0636 |
|
152 |
142 |
$13K |
| 86900 |
|
1,954 |
1,860 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
312 |
305 |
$11K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
287 |
281 |
$11K |
| 83735 |
|
2,764 |
2,680 |
$10K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
333 |
324 |
$10K |
| 73630 |
|
606 |
596 |
$10K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,950 |
2,897 |
$10K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,987 |
1,656 |
$9K |
| 84702 |
|
1,006 |
894 |
$9K |
| 90715 |
|
345 |
338 |
$9K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
619 |
596 |
$8K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,563 |
1,538 |
$8K |
| 73130 |
|
394 |
384 |
$8K |
| J2704 |
Injection, propofol, 10 mg |
1,434 |
1,410 |
$7K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,164 |
1,065 |
$7K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,366 |
1,286 |
$7K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,617 |
1,468 |
$7K |
| 87186 |
|
1,255 |
1,242 |
$7K |
| 73562 |
|
437 |
415 |
$6K |
| 83605 |
|
1,078 |
1,020 |
$6K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,020 |
999 |
$5K |
| 86901 |
|
2,117 |
2,017 |
$5K |
| A4649 |
Surgical supply; miscellaneous |
695 |
349 |
$5K |
| 81003 |
|
2,769 |
2,672 |
$5K |
| 73030 |
|
251 |
243 |
$5K |
| 86850 |
|
1,186 |
1,138 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
338 |
336 |
$4K |
| Z7610 |
|
284 |
194 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
2,688 |
2,305 |
$4K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
751 |
716 |
$3K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
831 |
779 |
$3K |
| 85027 |
|
790 |
764 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
80 |
78 |
$3K |
| 0324 |
|
120 |
119 |
$3K |
| 82948 |
|
1,112 |
978 |
$2K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
16 |
12 |
$2K |
| 84703 |
|
516 |
506 |
$2K |
| 73110 |
|
112 |
109 |
$2K |
| 93971 |
|
43 |
43 |
$2K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
18 |
18 |
$2K |
| J2060 |
Injection, lorazepam, 2 mg |
422 |
389 |
$2K |
| 99000 |
|
924 |
909 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
453 |
449 |
$2K |
| 85007 |
|
788 |
764 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
167 |
162 |
$1K |
| 72100 |
|
64 |
64 |
$1K |
| S0164 |
Injection, pantoprazole sodium, 40 mg |
137 |
125 |
$1K |
| 96376 |
|
191 |
187 |
$1K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
28 |
24 |
$1K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
181 |
169 |
$1K |
| 87420 |
|
327 |
325 |
$998.88 |
| 74018 |
|
68 |
63 |
$943.68 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
97 |
95 |
$915.86 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
69 |
57 |
$764.45 |
| 85380 |
|
247 |
246 |
$636.69 |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
12 |
12 |
$603.83 |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
13 |
13 |
$603.22 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
16 |
15 |
$541.47 |
| 0271 |
|
145 |
140 |
$480.25 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
15 |
12 |
$477.15 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
56 |
55 |
$460.04 |
| 76937 |
|
29 |
27 |
$433.51 |
| 87081 |
|
97 |
93 |
$406.29 |
| J1815 |
Injection, insulin, per 5 units |
20 |
12 |
$347.21 |
| 0459 |
|
21 |
18 |
$317.36 |
| 73080 |
|
26 |
25 |
$311.79 |
| 86141 |
|
45 |
45 |
$245.79 |
| 99070 |
|
49 |
37 |
$218.90 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
56 |
56 |
$216.29 |
| 84439 |
|
44 |
44 |
$161.11 |
| J1630 |
Injection, haloperidol, up to 5 mg |
44 |
37 |
$159.16 |
| 80061 |
Lipid panel |
55 |
52 |
$149.80 |
| 82550 |
|
41 |
40 |
$144.22 |
| 72040 |
|
12 |
12 |
$144.21 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
14 |
12 |
$131.98 |
| 94760 |
|
122 |
121 |
$117.02 |
| 12001 |
|
12 |
12 |
$84.00 |
| 59025 |
Fetal non-stress test |
13 |
12 |
$79.69 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
30 |
30 |
$65.68 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
21 |
16 |
$50.52 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
44 |
27 |
$49.05 |
| J1644 |
Injection, heparin sodium, per 1000 units |
14 |
13 |
$41.94 |
| 85651 |
|
13 |
13 |
$5.70 |